The use of nitazoxanide has previously yielded successful results in vitro against the coronavirus. aim present study was to examine efficacy at an early stage among healthcare workers exhibiting symptoms COVID‑19. This a prospective carried out in 2020. Healthcare personnel who presented with COVID‑19 symptoms, different 3 hospitals were invited take Paramix (nitazoxanide), 500 mg ora...

BACKGROUND Thuricin CD is a two-component antimicrobial, belonging to the recently designated sactibiotic subclass of bacteriocins. The aim of this study was to investigate the effects of thuricin CD, as well as the antibiotics, tigecycline, vancomycin, teicoplanin, rifampicin and nitazoxanide when used independently and when combined at low concentrations on the viability of Clostridium diffic...

Objective: To compare the efficacy of 3 days treatment with Nitazoxanide vs 5 Metronidazole in treating children diarrhea caused by Giardia-lamblia. Study Design: Randomized Controlled Trial Study. Setting: Department Pediatric, Women & Children Hospital MTI Bannu. Period: December 15, 2019 to May 2020. Material Methods: All 230 meeting inclusion criteria were enrolled study through OPD or ...

As there are increasing reports of fluoroquinolone resistance on use as a first- or second-line treatment for Helicobacter pylori (H pylori), we aimed at evaluation of the efficacy and safety of nitazoxanide-based regimen as a rescue regimen in Egyptian patients whose previous traditional treatment for H pylori infection failed.In total, 100 patients from the outpatient clinic of the Tropical m...

Paediatric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection rarely results in a critical presentation. It is not yet known which children are at particular risk of adverse outcomes. We describe paediatric case SARS-CoV-2 requiring Extra Corporeal Membrane Oxygenation (ECMO), who made full recovery after receiving dual antiviral therapy remdesivir and nitazoxanide.</...

Nitazoxanide (NTZ) has bactericidal activity against the H37Rv laboratory strain of Mycobacterium tuberculosis with a MIC of 16 μg/ml. However, its efficacy against clinical isolates of M. tuberculosis has not been determined. We found that NTZ's MIC against 50 clinical isolates ranged from 12 to 28 μg/ml with a median of 16 μg/ml and was unaffected by resistance to first- or second-line antitu...